TL;DR: In a typical SAFE round, the core document is the SAFE itself, plus board and stockholder approvals and basic closing paperwork. The document that quietly causes the most future pain is the side letter (usually pro rata rights or MFN), so treat it like a real deal term. If you use the YC post-money SAFE, you are usually choosing among three standard forms (cap, discount, or MFN) and optionally a pro rata side letter. The goal is one clean document set that is easy to administer at the next priced round, not a pile of bespoke promises you cannot track.
If you’re raising on SAFEs, you’re probably doing it for one reason: you want money in the bank without turning your life into a 200-page preferred stock financing. Fair.
But “simple” only describes the base instrument. The moment you add side letters, special information rights, or one-off promises to different investors, your SAFE round stops being simple in exactly the way that comes back to bite you at your seed or Series A.
When founders ask me about “SAFE financing documents,” what they usually mean is: what do I actually need to sign and approve so the investment is valid, fundable, and not a diligence fire drill later. This post is that answer, grounded in how most U.S. pre-seed and seed SAFE rounds actually close.
The core SAFE document set (what you usually need)
In most SAFE rounds, the “document set” is deliberately small. Investors are paying for economics now and getting stock later, so you are typically not negotiating a full governance package at this stage.
The SAFE itself. One SAFE per investor (or one per entity investing). It sets the conversion mechanics and the investor’s economic deal.
Optional term sheet. Sometimes you skip this and just agree on the cap/discount and round size over email. Sometimes you use a one-page term sheet to keep everyone aligned.
Board consent (or board resolutions). The board approves issuing the SAFEs and taking in the money.
Stockholder consent, if required. Many Delaware charters/bylaws do not require stockholder approval for SAFEs, but your documents might (especially if you have investor protective provisions already).
Closing deliverables. Wire instructions, a closing notice email, and a final PDF set circulated to all investors.
The common misconception is that “because it’s a SAFE” you can treat the corporate approvals like optional paperwork. You cannot. If you take money without proper authorization, it tends to surface later when a priced round lead investor’s counsel asks for your prior financing consents and cap table support. That is not when you want to discover a missing approval.
Which SAFE form are you using (and why it matters)
Most U.S. seed SAFEs you’ll see are based on the Y Combinator post-money forms. YC offers three post-money SAFE variants and an optional pro rata side letter. That’s not the only way to do a SAFE, but it’s the gravitational center of the market right now.
Valuation cap SAFE (no discount). A valuation cap is a ceiling on the price used to convert the SAFE into equity, so the investor converts as if the company were worth no more than the cap.
Discount SAFE (no cap). A discount means the investor converts at a percentage discount to the price paid by new money investors in the next priced equity round.
MFN SAFE (uncapped, no discount). MFN means “most favored nation.” If you later issue a SAFE (or similar instrument) with better terms, the MFN investor can elect to upgrade into those better terms.
Optional pro rata side letter. This is a short separate agreement that can give an investor the right to buy additional shares in the next equity financing to maintain their ownership percentage.
Post-money matters because it lets you measure ownership sold on each SAFE at signing, rather than waiting until conversion. Practically, each additional post-money SAFE dilutes you and your common stock pool rather than diluting earlier SAFE holders. That is not “bad,” but it is a reason to model dilution before you stack multiple SAFEs on the same cap.
The side letter: where “simple” rounds get complicated
If you only remember one thing from this post, make it this: the SAFE sets the economics, but the side letter often sets the future leverage.
Investors leading a SAFE round (or writing a larger check) often ask for a side letter. That practice is common. The question is whether the side letter is modest and standardized, or whether it quietly turns your cap table into a spreadsheet of bespoke obligations.
Pro rata rights. Reasonable when limited to the next priced equity round and tied to a true pro rata formula. Risky when drafted as a perpetual right across all future financings or as a hard ownership target.
MFN mechanics.MFN can be fine, but vague “more favorable terms” language creates disputes later. You want clear election mechanics and clear carve-outs.
Information rights. Light quarterly updates are common. Heavy reporting, audit rights, or anything that feels like public company obligations is usually out of place at SAFE stage.
Board observer rights. Sometimes requested by institutional investors. At pre-seed and seed, board observers can be more governance friction than value, especially if you later have multiple observers.
Expense reimbursement. Occasionally requested for lead investors. In small SAFE rounds, I generally view this as a poor trade unless it is tightly capped and truly reflects meaningful diligence costs.
Example #1: You give three different investors “pro rata rights,” each drafted a little differently. At your Series A, the new lead wants a clean allocation and a clean cap table. You spend two weeks reconciling who has what right, what “next financing” means, and whether those rights apply to a Series Seed, a Series A, or both.
Example #2: You issue an uncapped MFN SAFE early, then later raise on a capped SAFE when you have more traction. The MFN holder asks to amend into the capped terms. That may be exactly what you agreed to. The problem is when nobody tracked the MFN holder, the terms were ambiguous, or you issued multiple later SAFEs with different “better” terms.
Example #3 (M&A-aware): In an acquisition, buyer diligence teams will ask for all outstanding convertibles and side letters. If your “simple” SAFE round contains board observer rights, special consent rights, or odd information rights, the buyer may treat them like mini investors’ rights agreements that must be cleaned up before closing.
How SAFE rounds actually close (rolling closes, in practice)
Most SAFE rounds do not close like a priced round with a single “closing date” where everyone wires at 10:00 a.m. and you pop champagne at 10:03 a.m. Instead, you sign and collect wires on a rolling basis as investors are ready.
Pick one form and stick to it. One SAFE template for the round, not five versions floating around.
Standardize the variables. If the deal is “$X at a $Y cap,” make sure every SAFE matches that, and track exceptions intentionally.
Decide who signs first. In many rounds, the company signs the SAFE first and then circulates to the investor for countersignature, but the order matters less than consistency and tracking.
Use one closing email per investor. Final signed SAFE, wire instructions, and confirmation of receipt. Save it somewhere searchable.
Update the cap table as you go. Your future priced round lead will ask for your SAFE schedule. “We will reconstruct it later” is not a strategy.
Theory vs. reality: what matters in a SAFE doc set
Theory: because SAFEs are “standard,” you should spend your negotiation energy polishing every definition and every hypothetical corner case.
Reality: in most rounds, 80% of the outcome comes from a short list. Your cap and discount set the economics. Your post-money math determines how much you sold. Your side letters determine whether your next round feels clean or pre-allocated. Everything else is usually second-order.
Over-optimized: perfecting MFN language for a single investor when you are likely to raise multiple SAFEs later anyway. Focus instead: tracking who has MFN and having a clear process for later issuances.
Over-optimized: getting “one more tweak” to the SAFE form to feel bespoke. Focus instead: staying within the mainstream form so later counsel and investors do not treat your documents as exotic.
Over-optimized: negotiating information rights that nobody will use. Focus instead: setting investor expectations for communication and sending consistent updates.
If you remember one thing: keep the promises trackable
The practical takeaway is not “never sign a side letter.” It’s: do not sign side letters you cannot administer.
Before you sign, make a one-page schedule of every investor and every non-standard right (pro rata, MFN, information rights, observer).
Limit pro rata rights to the next equity financing unless you have a strong reason not to.
Model dilution for the whole round, not investor-by-investor.
Assume your next priced round counsel will read your SAFE package cold. Make it legible.
FAQ
Do I need a term sheet for a SAFE round? Usually no. If you have a lead investor and a clean SAFE form, you can often go straight to the SAFE after agreeing on cap or discount, round size, and any side letter asks.
What is the minimum I have to do to “properly” issue SAFEs? At a minimum, you need an executed SAFE with each investor, valid board approval, whatever stockholder approvals your governing documents require, and clean records showing who invested what and when.
Should I give pro rata rights on SAFEs? If the investor is meaningfully leading the round or writing a larger check, a limited pro rata right for the next equity financing can be market. Just understand you are pre-allocating some of your next round, and multiple pro rata promises can make the next round harder to lead.
Is an MFN SAFE “founder-friendly”? It can be, but it is not free. You are agreeing to revisit terms later if you offer someone else a better deal. If you expect to raise multiple SAFEs over time, MFN is manageable only if you track it and keep later issuances disciplined.
Do SAFE investors get votes, board seats, or blocking rights? Usually not from the SAFE itself. Those rights typically show up only after conversion in a priced round, or earlier through a side letter that grants information rights, observer rights, or other special terms.
Ryan RobertsStartup Lawyer
Ryan Roberts is a startup lawyer with more than two decades of experience advising on venture financings and M&A transactions totaling more than $1 billion. He is the author of the Amazon bestselling startup law book Acceleration.
